Regeneron Pharmaceuticals and its collaborators plan to sequence the exomes all of the UK Biobank participants by then end of 2019.
By the end of 2019, Regeneron plans sequence the exomes of all 500,000 participants in the UK Biobank.
The project, dubbed FinnGen, was announced this week and is slated to run through mid-2023.
With its recently launched BCRquest.com data analysis hub, BC Platforms has teamed with the Accelerated Cure Project for MS and Biogen.
Funded by Biogen, The University of Colorado, and The Global Down Syndrome Foundation, the project will analyze genetics and other biology in 1,000 individuals with the disorder.
Under the arrangement, OMRF will work with Biogen to analyze patient samples and identify biomarkers that indicate responses to particular therapies.
The company has added Biogen, Mount Sinai, and Thermo Fisher Scientific to its client roster and is exploring partnership opportunities with bioinformatics companies.
The firm's platform combines proprietary algorithms and software with its integrated genome-phenome database to uncover relationships between genetic variation and human health outcomes.
Under the Genomic Translation for ALS Clinical Care project, the partners will perform next-generation sequencing and clinical phenotyping on 1,500 ALS patients.
Drug companies are rushing toward genomic databases to inform their searches for new drugs, Reuters reports.
Cancer researcher Alan Rabson has died at 92, the New York Times reports.
As the National Guideline Clearinghouse goes dark, the ECRI Institute says it will pick up the slack.
In Genome Research this week: sequencing method examines proteins parasite uses to evade immune system, L1 insertions in cancer, and more.
The Atlantic reports on private Facebook support groups for people who receive unexpected parentage results from direct-to-consumer genetic tests.